Investigators using the revised Guidelines need two NIH pub! ications-- 
the "Administrative Practices Supplement" and the "Laboratory Safety 
Monograph." The former document is included in this volume. Investi gators 
may obtain the Monograph (238 pages) from the Office of Research Safety, 
National Cancer Institute, Rm. 2E47C, Bldg. 13, National Institutes of 
Health, Bethesda, Md. 20014. 
A memorandum on transition, included herein, accompanied the issuance 
of the revised Guidelines, setting January 2, 1979, as their effective date. 
The subsequent documents in this volume are arranged in chronological 
order. 
First is a transcript of the HEW public hearing on the proposed 
revised Guidelines, held in Washington, D.C., on September 15, 1978. 
Twenty-nine witnesses represented scientific, environmental, ethical, and 
governmental interests. Some wished to complete or modify their remarks 
in writing. All the submitted statements are reproduced here. 
An HEW Committee on Recombinant DNA, which had been formed to hold 
the public hearing and evaluate comments, also held meetings with NIH 
staff and small groups representing industry, the environment, and the 
scientific community. In addition, the Director, NIH, held a meeting with 
the Federal Interagency Advisory Committee on Recombinant DNA Research, 
October 12, 1978, to review the proposed revised Guidelines and the 
expanded role of the Interagency Committee in subsequent revisions. The 
minutes of this ninth meeting of the committee are included. This is 
followed by the program of a three-day workshop symposium for the chairmen 
of approximately 150 IBCs, held on November 19-21, 1978, at Reston, Va., 
in anticipation of the augmented institutional role under the revised 
Guidel ines. 
A notable event was the awarding of the 1978 Nobel Prize in Physiol- 
ogy or Medicine, for contributions to the field of recombinant DNA. 
Congratulatory messages are reproduced. 
A press release provides the names and affiliations of the newly 
constituted RAC, which has been expanded from 11 to 25 members to enhance 
its ability to deal with the legal, ethical, and other nonscientif ic 
issues surrounding recombinant DNA research. 
Finally, under separate cover, are two appendices. The first con- 
tains all the letters commenting on the NIH-proposed revision, arranged 
chronologically and preceded by an index of names. The second comprises 
the summons and answer of the still-pending case of Friends of the Earth 
v. Califano et al., alleging the failure of the defendants to comply with 
the National Environmental Policy Act in issuing the NIH Guidelines. 
v 
